Reported 18,985 shares, up 18,068 (1970.3%) from the prior quarter.
Reported value 1019.7%; share count 1970.3% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-12-31 | 7648 |
| 2024-03-31 | 6969 |
| 2024-06-30 | 78029 |
| 2024-09-30 | 99056 |
| 2024-12-31 | 101036 |
| 2025-03-31 | 242230 |
| 2025-06-30 | 336260 |
| 2025-09-30 | 483493 |
| 2025-12-31 | 359625 |
| 2026-03-31 | 540882 |
| 2026-06-30 | 2995079 |
| 2026-09-30 | 1347272 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 740,259 | -25,746 (-3.4%) | < 0.01% | $1,347,272 | 2026-11-13 | |
| Q2 2026 | Added | 766,005 | +715,408 (1413.9%) | < 0.01% | $2,995,079 | 2026-08-07 | |
| Q1 2026 | Added | 50,597 | +5,418 (12.0%) | < 0.01% | $540,882 | 2026-05-13 | |
| Q4 2025 | Added | 45,179 | +984 (2.2%) | < 0.01% | $359,625 | 2026-02-12 | |
| Q3 2025 | Added | 44,195 | +638 (1.5%) | < 0.01% | $483,493 | 2025-11-12 | |
| Q2 2025 | Added | 43,557 | +4,234 (10.8%) | < 0.01% | $336,260 | 2025-08-12 | |
| Q1 2025 | Added | 39,323 | +19,512 (98.5%) | < 0.01% | $242,230 | 2025-05-02 | |
| Q4 2024 | Added | 19,811 | +118 (0.6%) | < 0.01% | $101,036 | 2025-02-07 | |
| Q3 2024 | New | 19,693 | +19,693 (0.0%) | < 0.01% | $99,056 | 2024-11-13 | |
| Q2 2024 | Added | 18,985 | +18,068 (1970.3%) | < 0.01% | $78,029 | 2024-08-13 | |
| Q1 2024 | Unchanged | 917 | 0 (0.0%) | < 0.01% | $6,969 | 2024-05-10 | |
| Q4 2023 | New | 917 | +917 (0.0%) | < 0.01% | $7,648 | 2024-02-13 |
Who else reported the position
24 managers reported ELICIO THERAPEUTICS INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | Added | 226,297 | +10,611 | < 0.01% | $930,080 | 5 qtrs |
| ARMISTICE CAPITAL LLC | New | 100,000 | +100,000 | < 0.01% | $411,000 | 1 qtr |
| GEODE CAPITAL MANAGEMENT LLC | Added | 71,508 | +23,812 | < 0.01% | $293,930 | 5 qtrs |
| CM Management LLC | Reduced | 50,000 | -25,000 | 0.19% | $205,500 | 5 qtrs |
| Arena Investors LP | New | 50,000 | +50,000 | 1.64% | $205,500 | 1 qtr |
| Hudson Bay Capital Management LP | New | 48,720 | +48,720 | < 0.01% | $200,239 | 1 qtr |
| STATE STREET CORPORATION | Added | 21,900 | +4,300 | < 0.01% | $90,009 | 2 qtrs |
| BlackRock Inc This report | Added | 18,985 | +18,068 | < 0.01% | $78,029 | 3 qtrs |
| MEYER HANDELMAN CO | Unchanged | 13,899 | 0 | < 0.01% | $57,125 | 5 qtrs |
| BRIDGEWAY CAPITAL MANAGEMENT LLC | Unchanged | 12,500 | 0 | < 0.01% | $51,375 | 5 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 13, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 18,985
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.